Chmait Ramen, Franklin Patricia, Spector Stephen A, Hull Andrew D
Department of Reproductive Medicine, University of California San Diego, La Jolla, CA, USA.
J Perinatol. 2002 Jul-Aug;22(5):370-3. doi: 10.1038/sj.jp.7210748.
To assess the impact of highly active antiretroviral therapy, including a protease inhibitor (HAART/PI), on maternal glucose tolerance and fetal growth.
A retrospective chart review of pregnancy outcomes of human immunodeficiency virus-infected pregnant women receiving HAART/PI (n=41) or zidovudine monotherapy (n=23).
Abnormal 1-hour glucose tolerance tests (1hGTT) were observed in 30% of subjects receiving HAART/PI between 24 and 28 weeks' gestation. An elevated 1hGTT was associated with a significantly lower mean birth weight in subjects receiving HAART/PI compared to babies born to mothers with a normal 1hGTT (3.40+/-0.09 vs 3.00+/-0.18 kg, p<0.05, ANOVA).
HAART/PI therapy is associated with an increased rate of impaired glucose tolerance in pregnancy and impaired fetal growth. This finding merits further investigation.
评估包括蛋白酶抑制剂在内的高效抗逆转录病毒疗法（HAART/PI）对孕妇糖耐量和胎儿生长的影响。
对接受HAART/PI治疗的人类免疫缺陷病毒感染孕妇（n = 41）或齐多夫定单药治疗孕妇（n = 23）的妊娠结局进行回顾性图表审查。
在妊娠24至28周期间，接受HAART/PI治疗的受试者中，30%的人1小时糖耐量试验（1hGTT）异常。与1hGTT正常的母亲所生婴儿相比，接受HAART/PI治疗的受试者中1hGTT升高与平均出生体重显著降低相关（3.40±0.09 vs 3.00±0.18 kg，p<0.05，方差分析）。
HAART/PI治疗与妊娠糖耐量受损率增加和胎儿生长受损有关。这一发现值得进一步研究。
